159 : Hormones, Menopause, and the Cost of Saying No

Dr. Jenn Simmons is joined by Dr. Louise Newson, a hormone-focused physician and menopause educator, for a wide-ranging conversation about the difference between bioidentical and synthetic hormones, why hormone fear persists in medicine, and how that fear affects women’s long-term health. They also dig into breast cancer, BRCA mutations, perimenopause, testosterone, compounding, and why shared decision-making matters more than blanket rules. Key topics Dr. Louise Newson shares how her medical path moved from internal medicine and pathology into general practice, medical writing, and ultimately menopause and hormone care. She explains why the Women’s Health Initiative and other early studies created lasting confusion by mixing synthetic hormones with bioidentical hormones. Dr. Newson breaks down the biological difference between endogenous hormones and synthetic compounds, using receptor biology and chemical structure to show why they are not interchangeable. The conversation examines why many clinicians still fear hormone therapy, including outdated warnings, guideline dependence, pharma influence, and professional ego. Dr. Newson argues that menopause is not just a “natural transition” but a hormone deficiency with real biological consequences, especially for bone, cardiovascular, brain, and metabolic health. They discuss the misconception that hormones should only be used briefly, and why some women benefit from continuing treatment based on symptoms, quality of life, and future risk reduction. The episode covers testosterone in women, including why it is underused, why it is often misunderstood as only a libido hormone, and how it can affect mood, energy, sleep, joints, and cognition. They explore how perimenopause is best approached by assessing progesterone, estradiol, and testosterone separately rather than relying on one broad label. Dr. Newson addresses compounding, explaining why individualized preparations can be useful and why “compounded” does not automatically mean unsafe. The discussion moves into breast cancer and BRCA mutations, with a focus on why hormone decisions should be individualized rather than ruled out by category. They emphasize that women need better information to make informed choices, and that refusing to offer hormone treatment can itself cause harm. Timestamps 00:00 - Why Dr. Louise Newson is such a trusted voice on hormones 01:17 - Losing her father young and the path into medicine 03:39 - From prescribing HRT to becoming a medical writer 04:04 - The WHI study and why it changed everything 05:55 - Why antidepressants were replacing hormone care 07:32 - Synthetic hormones versus bioidentical hormones 09:33 - How receptor biology explains the difference 10:32 - Chemical examples that show how small changes matter 11:30 - Why WHO classified ethinyl estradiol as carcinogenic 13:34 - Why warnings and guidelines keep the fear alive 15:28 - The vacuum created when doctors stopped learning hormones 16:41 - Training more than 33,000 clinicians in menopause care 18:57 - Why gynecologists are not necessarily hormone experts 19:24 - Why endocrinology and psychiatry often miss the issue 20:49 - Is menopause a disease or a normal transition? 22:15 - Why early menopause raises the stakes 23:34 - Why hormone therapy should remain a choice 24:27 - What happens when the body adapts to low hormones 25:41 - Why supplements cannot replace estradiol, progesterone, or testosterone 28:55 - What older women discover when they finally try hormones 29:57 - The so-called window of opportunity after age 60 31:31 - Why hormones may still help women with heart disease 33:41 - Why there will